Longboard Pharmaceuticals Inc

NASDAQ:LBPHUnited States

Nov 7, 2024

Show headlines and story abstract

• Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: LBPH
  current portion 267 475 ----------- ---------- Total current liabilities 18,352 9,774 Right-of-use liabilities, net of current portion 3,467 -- Commitments and contingencies Stockholders' equity: Preferred stock, $0.0001 par value; authorized shares - 10,000,000 at September 30, 2024 and December 31, 2023; issued and outstanding shares - none at September 30, 2024 and December 31, 2023 -- -- Voting common stock, $0.0001 par value; authorized shares - 300,000,000 at September 30, 2024 and December 31, 2023; issued and outstanding shares - 34,419,536 and 22,096,494 at September 30, 2024 and December 31, 2023, respectively 3 2 Non-voting common stock, $0.0001 par value; authorized shares - 10,000,000 at September 30, 2024 and December 31, 2023; issued and outstanding shares - 4,609,500 and 2,420,755 at September 30, 2024 and December 31, 2023, respectively -- -- Additional paid-in capital 476,358 181,563 Accumulated other comprehensive income (loss) 700 (78) Accumulated deficit (201,875) (140,564) ----------- ---------- Total stockholders' equity 275,186 40,923 ----------- ---------- Total liabilities and stockholders' equity $ 297,005 $ 50,697 =========== ========== LONGBOARD PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share data) 2024 2023 2024 2023 -------------------- ------------ ------------ --------------- -------------- Operating expenses: Research and development $ 21,450 $ 10,488 $ 55,065 $ 31,554 General and administrative 6,674 3,094 16,812 9,632 ---------- ---------- ---------- ---------- Total operating expenses 28,124 13,582 71,877 41,186 ---------- ---------- ---------- ---------- Loss from operations (28,124) (13,582) (71,877) (41,186) Interest income, net 3,655 662 10,693 1,838 Other expense (71) (14) (127) (41) ---------- ---------- ---------- ---------- Net loss $ (24,540) $ (12,934) $ (61,311) $ (39,389) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.63) $ (0.55) $ (1.63) $ (1.77) ========== ========== ========== ========== Weighted-average shares outstanding, basic and diluted 38,957,524 23,487,457 37,724,402 22,299,998 ========== ========== ========== ========== Comprehensive loss: Net loss $ (24,540) $ (12,934) $ (61,311) $ (39,389) Unrealized gain on short-term investments 1,175 109 778 511 ---------- ---------- ---------- ---------- Comprehensive loss $ (23,365) $ (12,825) $ (60,533) $ (38,878) ========== ========== ========== ==========
  

• Press Release: Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones

  4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: LBPH
  current portion 267 475 ----------- ---------- Total current liabilities 18,352 9,774 Right-of-use liabilities, net of current portion 3,467 -- Commitments and contingencies Stockholders' equity: Preferred stock, $0.0001 par value; authorized shares - 10,000,000 at September 30, 2024 and December 31, 2023; issued and outstanding shares - none at September 30, 2024 and December 31, 2023 -- -- Voting common stock, $0.0001 par value; authorized shares - 300,000,000 at September 30, 2024 and December 31, 2023; issued and outstanding shares - 34,419,536 and 22,096,494 at September 30, 2024 and December 31, 2023, respectively 3 2 Non-voting common stock, $0.0001 par value; authorized shares - 10,000,000 at September 30, 2024 and December 31, 2023; issued and outstanding shares - 4,609,500 and 2,420,755 at September 30, 2024 and December 31, 2023, respectively -- -- Additional paid-in capital 476,358 181,563 Accumulated other comprehensive income (loss) 700 (78) Accumulated deficit (201,875) (140,564) ----------- ---------- Total stockholders' equity 275,186 40,923 ----------- ---------- Total liabilities and stockholders' equity $ 297,005 $ 50,697 =========== ========== LONGBOARD PHARMACEUTICALS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except share and per share data) 2024 2023 2024 2023 -------------------- ------------ ------------ --------------- -------------- Operating expenses: Research and development $ 21,450 $ 10,488 $ 55,065 $ 31,554 General and administrative 6,674 3,094 16,812 9,632 ---------- ---------- ---------- ---------- Total operating expenses 28,124 13,582 71,877 41,186 ---------- ---------- ---------- ---------- Loss from operations (28,124) (13,582) (71,877) (41,186) Interest income, net 3,655 662 10,693 1,838 Other expense (71) (14) (127) (41) ---------- ---------- ---------- ---------- Net loss $ (24,540) $ (12,934) $ (61,311) $ (39,389) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.63) $ (0.55) $ (1.63) $ (1.77) ========== ========== ========== ========== Weighted-average shares outstanding, basic and diluted 38,957,524 23,487,457 37,724,402 22,299,998 ========== ========== ========== ========== Comprehensive loss: Net loss $ (24,540) $ (12,934) $ (61,311) $ (39,389) Unrealized gain on short-term investments 1,175 109 778 511 ---------- ---------- ---------- ---------- Comprehensive loss $ (23,365) $ (12,825) $ (60,533) $ (38,878) ========== ========== ========== ==========